Skip to content
CancerIndex

Publication

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

Authors not recorded

Cancer Res2010PMID 20551065stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (4)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 4

Curated evidence

Evidence citing this paper (3)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
20551065
Run
ING-CIVIC-20260908-000001
Open at source
CuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
BRAF V600D1
VemurafenibMelanomaPredictiveDSupports Sensitivity Response4accepted
EID4489

In an in vitro study, the WM2664 and WM239A cell lines expressing BRAF V600D were associated with increased sensitivity to vemurafenib treatment, as compared to cell lines expressing BRAF wild-type. S… (full text at CIViC)

PMID 20551065 · Yang et al., 2010 · Open in CIViC

civic
BRAF V600E1
VemurafenibMelanomaPredictiveDSupports Sensitivity Response3submitted
EID3753

In an in vitro study, several cell lines (including MALME-3M, Colo829, Colo38, A375 and SK-MEK28) expressing BRAF V600E were associated with increased sensitivity to vemurafenib (RG7204) treatment, as… (full text at CIViC)

PMID 20551065 · Yang et al., 2010 · Open in CIViC

civic
BRAF V600R1
VemurafenibMelanomaPredictiveDSupports Sensitivity Response3submitted
EID4171

In an in vitro study, the WM1341D cell line expressing BRAF V600R was associated with increased sensitivity to vemurafenib treatment, as compared to cell lines expressing BRAF wild-type. Sensitivity w… (full text at CIViC)

PMID 20551065 · Yang et al., 2010 · Open in CIViC

civic